Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Apr 1;50(4):565-575.
doi: 10.1097/CCM.0000000000005270.

Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury

Fabienne Venet  1 , Julien Textoris  1 , Sophie Blein  1 , Mary-Luz Rol  2 , Maxime Bodinier  1 , Bertrand Canard  2 , Pierre Cortez  3 , Boris Meunier  1 , Lionel K Tan  4 , Craig Tipple  4 , Laurence Quemeneur  3 , Frédéric Reynier  2 , Philippe Leissner  2 , Christophe Védrine  2 , Yves Bouffard  1 , Benjamin Delwarde  1 , Olivier Martin  1 , Thibaut Girardot  1 , Cyrille Truc  1 , Andrew D Griffiths  5 , Virginie Moucadel  1 , Alexandre Pachot  1 , Guillaume Monneret  1 , Thomas Rimmelé  1 ; REALISM study group
Affiliations
Observational Study

Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury

Fabienne Venet et al. Crit Care Med. .

Erratum in

Abstract

Objectives: The host response plays a central role in the pathophysiology of sepsis and severe injuries. So far, no study has comprehensively described the overtime changes of the injury-induced immune profile in a large cohort of critically ill patients with different etiologies.

Design: Prospective observational cohort study.

Setting: Adult ICU in a University Hospital in Lyon, France.

Patients: Three hundred fifty-three septic, trauma, and surgical patients and 175 healthy volunteers were included in the REAnimation Low Immune Status Marker study.

Interventions: None.

Measurements and main results: Extensive immune profiling was performed by assessing cellular phenotypes and functions, protein, and messenger RNA levels at days 1-2, 3-4, and 5-7 after inclusion using a panel of 30 standardized immune markers. Using this immunomonitoring panel, no specificity in the immune profile was observed among septic, trauma, and surgical patients. This common injury-induced immune response was characterized by an initial adaptive (i.e., physiologic) response engaging all constituents of the immune system (pro- and anti-inflammatory cytokine releases, and innate and adaptive immune responses) but not associated with increased risk of secondary infections. In contrary, the persistence in a subgroup of patients of profound immune alterations at the end of the first week after admission was associated with increased risk of secondary infections independently of exposure to invasive devices. The combined monitoring of markers of pro-/anti-inflammatory, innate, and adaptive immune responses allowed a better enrichment of patients with risk of secondary infections in the selected population.

Conclusions: Using REAnimation Low Immune Status Marker immunomonitoring panel, we detected delayed injury-acquired immunodeficiency in a subgroup of severely injured patients independently of primary disease. Critically ill patients' immune status could be captured through the combined monitoring of a common panel of complementary markers of pro-/anti-inflammatory, innate, and adaptive immune responses. Such immune monitoring needs to be incorporated in larger study cohorts with more extensive immune surveillance to develop specific hypothesis allowing for identification of biological systems affecting altered immune function related to late infection in the setting of acute systemic injury.

Trial registration: ClinicalTrials.gov NCT02638779.

PubMed Disclaimer

Conflict of interest statement

Drs. Textoris, Blein, Moucadel, and Pachot are employees of bioMérieux SA, an in vitro diagnostic company. Drs. Venet, Bouffard, Delwarde, Martin, Girardot, Truc, Monneret, and Rimmelé are employees of Hospices Civils de Lyon. Drs. Venet, Textoris, Blein, Moucadel, Pachot, Monneret, and Rimmelé work in a joint research unit, cofunded by the Hospices Civils de Lyon and bioMérieux. Drs. Venet, Textoris, Pachot, and Monneret are coinventors in patent applications covering the following markers: CX3CR1, CD127, interleukin-10, and S100A9. Drs. Tan and Tipple are employees of and hold stock and shares in GlaxoSmithKline. Dr. Cortez is an employee of Sanofi Pasteur. Dr. Cortez was an employee of Sanofi. Drs. Venet’s, Textoris’s, Blein’s, Rol’s, Canard’s, Tipple’s, Vedrine’s, Martin’s, Girardot’s, Truc’s, Griffiths’s, Pachot’s, and Rimmelé’s institutions received funding from the Agence Nationale de la Recherche through a grant awarded to BIOASTER (ANR-10-AIRT-03), bioMerieux, Sanofi, and GSK. Dr. Bodinier received funding from HCL. Drs. Quemeneur and Moucadel disclosed work for hire. Dr. Quemeneur disclosed that his partner is an employee of Bioaster. Dr. Martin disclosed government work. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Comment in

  • Inflamed.
    Nyquist P. Nyquist P. Crit Care Med. 2022 Apr 1;50(4):691-693. doi: 10.1097/CCM.0000000000005293. Crit Care Med. 2022. PMID: 35311777 No abstract available.

References

    1. Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801–810
    1. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013; 369:840–851
    1. Shankar-Hari M, Phillips GS, Levy ML, et al.; Sepsis Definitions Task Force: Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:775–787
    1. Rudd KE, Johnson SC, Agesa KM, et al.: Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study. Lancet 2020; 395:200–211
    1. Reinhart K, Daniels R, Kissoon N, et al.: Recognizing sepsis as a global health priority—a WHO resolution. N Engl J Med 2017; 377:414–417

Publication types

Associated data